PolyPid (PYPD)
Develops local prolonged-release therapies led by D-PLEX100 for surgical-site infection prevention.
Something off on this page? Send us feedback.
Develops local prolonged-release therapies that pair drugs with a controlled-release platform. Its business centers on D-PLEX100, a surgical-site infection candidate, and depends on FDA review and the Azurity commercialization partnership.
Pairs active pharmaceutical ingredients with a controlled-release platform that delivers therapy locally at the point of care. Its lead candidate, D-PLEX100, releases doxycycline at the surgical site after wound closure to help prevent surgical-site infection following abdominal colorectal surgery.
Clinical development shifted after the first SHIELD study missed its overall primary endpoint. A later SHIELD study in patients with large abdominal incisions met its primary and key secondary endpoints, and the company completed a rolling NDA submission to the FDA.
Commercialization in the United States and Canada is governed by an exclusive partnership with Azurity Pharmaceuticals. The business remains centered on regulatory review of D-PLEX100 and execution of that partnership.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
| Date | Firm | Action | Rating | Prior target | Target |
|---|---|---|---|---|---|
| Jul 22, 2026 | Craig-Hallum | Target | $10 | $12 | |
| Jul 22, 2026 | H.C. Wainwright | Reiterate | Buy | $13 |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $6.6M · Total debt $1.6M · Total assets $15.2M · Shareholders' equity $5.4M
- Revenue
- $0
- Operating income
- $7.8M
- Net income
- −$7.8M
No dividends on record.
| Institutions20 holders · as of Mar 31, 2026 | 16.34% | 3.12M ADS | |
| Insiders8 holders · as of Mar 26, 2026 | 16.13% | 3.08M ADS | |
| Strategic holders1 holder · as of May 4, 2026 | 26.21% | 5.00M ADS | |
| Otherremainder | 41.32% | 7.88M ADS |
19.08M ADS (1 ADS = 3 ordinary shares) as of Aug 21, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
The share count is from the company's Dec 2024 annual report; nothing newer is on file here.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Aurum Ventures M.K.I. Ltd.Strategic | 26.21% | 5.00M | 13Gfiled May 4, 2026 ↗ |
Orin HirschmanInsider | 9.40% | 1.79M | 13Gfiled Jan 30, 2026 ↗ |
Aigh Capital Management LLCInstitution | 8.35% | 1.59M ADS | 13Fas of Mar 31, 2026 |
Rodney HodgesInsider | 3.92% | 747,589 | 13Gfiled Feb 14, 2025 ↗ |
Rosalind Advisors, Inc.Institution | 3.13% | 597,926 ADS | 13Fas of Mar 31, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Johnson & Johnson
Antibacterial sutures used in surgical-site-infection prevention bundles
- BD
Preoperative skin antisepsis used to reduce bacteria before surgery
- Stryker
Preoperative CHG cloths addressing surgical-site-infection risk factors
- Zimmer Biomet
Antibiotic-loaded bone cement delivering local gentamicin in orthopedics
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| PolyPid | $5.28 | −0.94% | $101.1M | — | — | — | — |
| Johnson & Johnson | $275.01 | −0.08% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| BD | $189.24 | +0.88% | $51.67B | 56.5 | 14.2 | 2.5 | −9.6% |
| Stryker | $314.00 | +0.58% | $119.68B | 32.4 | 19.4 | 4.6 | +9.4% |
| Zimmer Biomet | $100.09 | +0.60% | $19.25B | 24.2 | 11.4 | 2.3 | +4.8% |
| Median | 32.1 | 16.8 | 3.6 | +5.7% |